This 2003 review critically examines the efficacy and safety of chromium picolinate (Cr(pic)₃) as a nutritional supplement. While chromium is believed to play a role in carbohydrate and lipid metabolism, human studies have not demonstrated significant benefits of Cr(pic)₃ supplementation on body composition, weight loss, or muscle development, even when
This 2017 single-center, open-label phase II trial evaluated the efficacy and safety of weekly intravenous ascorbic acid (AA) in 23 chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). The dosing regimen included 5 g in week 1, 30 g in week 2, and 60 g weekly from weeks 3 to
This phase 1b/2a multicenter, open-label trial evaluated Descartes-08, an autologous RNA-engineered anti-BCMA CAR T-cell therapy, in 14 adults with generalized myasthenia gravis (MG). Unlike conventional DNA-based CAR T therapies, Descartes-08 utilizes transient mRNA expression, eliminating the need for lymphodepletion. Participants received up to six weekly infusions. The therapy was well
This review discusses the clinical experience with intravenous ferric carboxymaltose (FCM) for treating iron deficiency anemia (IDA) in adults intolerant to or unresponsive to oral iron, or with nondialysis-dependent chronic kidney disease. FCM allows administration of up to 750 mg per dose (totaling 1500 mg over two doses), delivered over
This randomized, multicenter, double-blind clinical trial assessed the safety and efficacy of intravenous ferumoxytol compared to ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA) unresponsive or intolerant to oral iron. A total of 1,997 patients received either ferumoxytol (n=997) or FCM (n=1000) over ≥15 minutes on days 1
This study evaluated the safety and pharmacokinetics of intravenous citrulline in infants and children undergoing congenital heart surgery. In Phase 1, a dose-escalation protocol (50, 100, 150 mg/kg) was used, with a target plasma citrulline trough of 80–100 µmol/L. The 150 mg/kg dose achieved this target. Due to citrulline’s short
This 2015 pilot study evaluated the safety and efficacy of dexamphetamine combined with diet and exercise in 14 obese adults over a 6-month period. Participants received up to 30 mg of dexamphetamine twice daily. Twelve completed the treatment, achieving a mean weight loss of 10.6 kg (95% CI: 5.8–15.5, p
This 2013 randomized controlled trial assessed the impact of glucomannan supplementation on weight loss in 53 overweight and moderately obese adults over an 8-week period. Participants consumed 1.33 grams of glucomannan or placebo with water before meals. The study found no significant differences between the glucomannan and placebo groups in
This review examines the evolving evidence on the cardiovascular safety of testosterone replacement therapy (TRT) in men with hypogonadism. While earlier observational studies raised alarms over increased cardiovascular risks—including myocardial infarction and stroke—recent randomized trials, particularly the TRAVERSE study, provide reassurance that TRT does not significantly increase the risk of
This 2023 prospective, open-label pilot study assessed the efficacy and safety of a 0.5% silymarin-loaded antioxidant serum (SAS) as an adjunct treatment in 22 Korean patients with mild-to-moderate acne vulgaris. Over four weeks, patients applied the serum twice daily in addition to their regular acne treatments. The study reported reductions
